CY1109862T1 - Χρηση συνθεσεων που περιεχουν ανταγωνιστες των καππα υποδοχεων των οπιοειδων για τη θεραπεια διασχιστικων διαταραχων - Google Patents
Χρηση συνθεσεων που περιεχουν ανταγωνιστες των καππα υποδοχεων των οπιοειδων για τη θεραπεια διασχιστικων διαταραχωνInfo
- Publication number
- CY1109862T1 CY1109862T1 CY20101100188T CY101100188T CY1109862T1 CY 1109862 T1 CY1109862 T1 CY 1109862T1 CY 20101100188 T CY20101100188 T CY 20101100188T CY 101100188 T CY101100188 T CY 101100188T CY 1109862 T1 CY1109862 T1 CY 1109862T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- disorders
- intermittent
- opioid receptor
- compositions containing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000003840 Opioid Receptors Human genes 0.000 title 1
- 108090000137 Opioid Receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108020001588 κ-opioid receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006015733A DE102006015733A1 (de) | 2006-04-04 | 2006-04-04 | Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit |
| DE102006016991A DE102006016991A1 (de) | 2006-04-11 | 2006-04-11 | Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen |
| EP07727719A EP2001456B1 (de) | 2006-04-04 | 2007-04-03 | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109862T1 true CY1109862T1 (el) | 2014-09-10 |
Family
ID=38110094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100188T CY1109862T1 (el) | 2006-04-04 | 2010-02-25 | Χρηση συνθεσεων που περιεχουν ανταγωνιστες των καππα υποδοχεων των οπιοειδων για τη θεραπεια διασχιστικων διαταραχων |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8063059B2 (https=) |
| EP (1) | EP2001456B1 (https=) |
| JP (1) | JP5128578B2 (https=) |
| AT (1) | ATE450256T1 (https=) |
| AU (1) | AU2007236003B2 (https=) |
| CA (1) | CA2646899C (https=) |
| CY (1) | CY1109862T1 (https=) |
| DE (1) | DE502007002185D1 (https=) |
| DK (1) | DK2001456T3 (https=) |
| EA (1) | EA014820B1 (https=) |
| ES (1) | ES2337622T3 (https=) |
| HR (1) | HRP20100113T1 (https=) |
| PL (1) | PL2001456T3 (https=) |
| PT (1) | PT2001456E (https=) |
| RS (1) | RS51211B (https=) |
| SI (1) | SI2001456T1 (https=) |
| WO (1) | WO2007115975A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5345637B2 (ja) | 2008-01-22 | 2013-11-20 | イーライ リリー アンド カンパニー | κ選択的オピオイド受容体アンタゴニスト |
| ES2694352T3 (es) * | 2013-12-20 | 2018-12-20 | H. Lundbeck A/S | Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas |
| US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| LT3137081T (lt) | 2014-04-28 | 2018-02-26 | Orphomed, Inc. | Buprenorfino dimeras ir jo naudojimas gydant virškinamojo trakto sutrikimus |
| US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023170554A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028612A (en) * | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
| US5780479A (en) * | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
| US6242456B1 (en) * | 1998-03-09 | 2001-06-05 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors |
| US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| EP1365756A2 (en) * | 2000-08-15 | 2003-12-03 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| JP2004518654A (ja) * | 2000-12-21 | 2004-06-24 | ザ マクレーン ホスピタル コーポレーション | 鬱病の治療法 |
| US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| CA2521396A1 (en) * | 2003-04-04 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| JP2007526328A (ja) * | 2004-03-02 | 2007-09-13 | ファルマシア コーポレーション | 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物 |
| CN103087133B (zh) * | 2004-05-26 | 2016-09-14 | 伊诺泰克制药公司 | 嘌呤衍生物作为腺苷a1受体激动剂及其用法 |
| EP1750675B1 (en) * | 2004-06-02 | 2008-10-29 | Galephar M/F | Stable oral pharmaceutical compositions of buprenorphine and salt thereof |
-
2007
- 2007-04-03 JP JP2009503576A patent/JP5128578B2/ja not_active Expired - Fee Related
- 2007-04-03 US US12/296,125 patent/US8063059B2/en not_active Expired - Fee Related
- 2007-04-03 AT AT07727719T patent/ATE450256T1/de active
- 2007-04-03 ES ES07727719T patent/ES2337622T3/es active Active
- 2007-04-03 DE DE502007002185T patent/DE502007002185D1/de active Active
- 2007-04-03 PT PT07727719T patent/PT2001456E/pt unknown
- 2007-04-03 PL PL07727719T patent/PL2001456T3/pl unknown
- 2007-04-03 EA EA200802104A patent/EA014820B1/ru not_active IP Right Cessation
- 2007-04-03 CA CA2646899A patent/CA2646899C/en not_active Expired - Fee Related
- 2007-04-03 HR HR20100113T patent/HRP20100113T1/hr unknown
- 2007-04-03 WO PCT/EP2007/053248 patent/WO2007115975A2/de not_active Ceased
- 2007-04-03 DK DK07727719.2T patent/DK2001456T3/da active
- 2007-04-03 RS RSP-2010/0089A patent/RS51211B/sr unknown
- 2007-04-03 AU AU2007236003A patent/AU2007236003B2/en not_active Ceased
- 2007-04-03 EP EP07727719A patent/EP2001456B1/de active Active
- 2007-04-03 SI SI200730163T patent/SI2001456T1/sl unknown
-
2010
- 2010-02-25 CY CY20101100188T patent/CY1109862T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8063059B2 (en) | 2011-11-22 |
| ES2337622T3 (es) | 2010-04-27 |
| SI2001456T1 (sl) | 2010-04-30 |
| AU2007236003A1 (en) | 2007-10-18 |
| RS51211B (sr) | 2010-12-31 |
| HRP20100113T1 (hr) | 2010-04-30 |
| AU2007236003B2 (en) | 2012-10-18 |
| EA014820B1 (ru) | 2011-02-28 |
| EP2001456B1 (de) | 2009-12-02 |
| JP2009532434A (ja) | 2009-09-10 |
| DK2001456T3 (da) | 2010-04-12 |
| DE502007002185D1 (de) | 2010-01-14 |
| CA2646899A1 (en) | 2007-10-18 |
| US20090181999A1 (en) | 2009-07-16 |
| WO2007115975A2 (de) | 2007-10-18 |
| ATE450256T1 (de) | 2009-12-15 |
| CA2646899C (en) | 2014-05-06 |
| PL2001456T3 (pl) | 2010-05-31 |
| WO2007115975A3 (de) | 2008-02-14 |
| EA200802104A1 (ru) | 2009-04-28 |
| JP5128578B2 (ja) | 2013-01-23 |
| PT2001456E (pt) | 2010-03-03 |
| EP2001456A2 (de) | 2008-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109862T1 (el) | Χρηση συνθεσεων που περιεχουν ανταγωνιστες των καππα υποδοχεων των οπιοειδων για τη θεραπεια διασχιστικων διαταραχων | |
| CY1123549T1 (el) | Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης | |
| CY1122330T1 (el) | Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης | |
| EA201171403A1 (ru) | Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик | |
| CY1113024T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων | |
| CY1111454T1 (el) | Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων | |
| CY1117143T1 (el) | Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης | |
| CY1112067T1 (el) | Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας | |
| CY1117424T1 (el) | Βενζοδιαζεπινικος αναστολεας bromodomain | |
| EA201190017A1 (ru) | Аминоэфирные производные алкалоидов и их медицинские композиции | |
| EA201001253A1 (ru) | N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d | |
| EA201101190A1 (ru) | Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение | |
| EA201170624A1 (ru) | Изоникотинамидные антагонисты рецепторов орексинов | |
| CR10379A (es) | Composiones farmaceuticas de antagonistas del anticuerpo anti-cd40. | |
| EA201100161A1 (ru) | Производные хинуклидина карбоната и их медицинские композиции | |
| MA32200B1 (fr) | Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation | |
| EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
| NO20084531L (no) | Bruk av flibanserin for behandling av post-menopause seksuell lyst lidelser | |
| EA200970341A1 (ru) | Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов | |
| EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
| EA201170753A1 (ru) | Налмефена гидрохлорид дигидрат | |
| EA200801997A1 (ru) | Новые соединения | |
| EA201171074A1 (ru) | Цитотоксические конъюгаты с соединением, связывающим рецептор нейропептида y | |
| CY1115975T1 (el) | Ταπενταδολη για τη θεραπεια πονου σε αρθριτιδα | |
| EA201170356A1 (ru) | Полиморфные и аморфные формы лакозамида и аморфные композиции |